News

Sponsorship of patients' groups by drug companies should be made transparent

BMJ 2006; 333 doi: 10.1136/bmj.39062.360289.DB (Published 14 December 2006)
Cite this as: BMJ 2006;333:1238.5

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Annette Tuffs
  1. 1Heidelberg

    Drug companies are sponsoring more and more groups for patients in Germany to increase demand for their products, but many members remain unaware of their involvement, a study has found.

    The firms are also advertising their products on what seem to be independent websites, despite laws that ban advertising prescription medicines to the public.

    The study, by the Zentrum für Sozialpolitik of Bremen University, was commissioned by Germany's state health insurance companies and focused on the funding of groups for patients with chronic diseases, such as Alzheimer's disease and eczema.

    At present, health insurance companies are the main sponsor of patients' groups, spending a total €28m (£19m; $37m) in 2005, but drug companies are increasingly moving into the area.

    A quarter of patients' …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular